Moxonidine
Phase 2Small molecule
Moxonidine is one of 60 small molecule programs targeting Obesity. It is currently in Phase 2.
3
Indications
16
Total Trials
2
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
176 competitors in Obesity
#DrugCompanyPhaseTrials
1Retatrutide
Eli LillyPhase 3
Berobenatide
PfizerPhase 3
Cagrisema
Novo NordiskPhase 3
Eloralintide
Eli LillyPhase 3
Naltrexone-Bupropion Combination
CCurrax Pharmaceuticals
Phase 3
Survodutide
Boehringer IngelheimPhase 3
Semaglutide or Tirzepatide
NNational and Kapodistrian University of Athens
Phase 3
Moxonidine
SSolvay Pharmaceuticals
Phase 2
Actemra
RochePreclinical
Avapro
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hypertension3 trials
Obesity3 trials
6 more indications
Postmenopausal Women1 trial
Kidney Disease1 trial
Unspecified2 trials
Moxonidine Effects on Neuropeptide Y
Completed·—·Phase 4·NCT05147753·90 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Moxonidine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSolvay Pharmaceuticals